Clinical, pathological, biochemical and genomic characteristics of poorly differentiated thyroid cancer

@inproceedings{Ibrahimpai2018ClinicalPB,
  title={Clinical, pathological, biochemical and genomic characteristics of poorly differentiated thyroid cancer},
  author={Tihana Ibrahimpa{\vs}i{\'c}},
  year={2018}
}
This is a comprehensive study of one of the largest cohort of poorly differentiated thyroid carcinoma (PDTC) patients reported in the literature, diagnosed by criteria of proliferative grading and treated surgically at a tertiary care academic center, with or without adjuvant therapy. The main objectives were: to report on clinicopathological, biochemical and genomic characteristics of PDTC patients, to correlate those characteristics with outcome and to report on the patterns of treatment… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 97 REFERENCES

NCCN clinical practice guidelines in oncology: thyroid cancer

RM Tuttle
  • Available at: www.nccn. org/professionals/physician_gls/PDF/thyroid.pdf (accessed February
  • 2016
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Thyroid cancer mortality and incidence: a global overview.

  • International journal of cancer
  • 2015
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Outcomes in patients with poorly differentiated thyroid carcinoma.

  • The Journal of clinical endocrinology and metabolism
  • 2014
VIEW 6 EXCERPTS

TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas

  • The Journal of clinical endocrinology and metabolism
  • 2014
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Update on differentiated thyroid cancer staging.

  • Endocrinology and metabolism clinics of North America
  • 2014
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Integrative Genomics Viewer

  • Nature Biotechnology
  • 2011
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL